Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Iduronic acid (IdoA) is a uronic acid monosaccharide and a major structural component of glycosaminoglycans such as heparin, heparan sulfate, chondroitin sulfate, and dermatan sulfate[3][7][8]. It exists as a C-5 epimer of glucuronic acid and imparts considerable conformational flexibility to the polysaccharide chains it inhabits. This flexibility allows glycosaminoglycans to accommodate and bind various proteins, contributing to biological processes such as coagulation, cell signaling, inflammation, wound healing, and cancer progression[2][6][8]. Iduronic acid is not itself a therapeutic target but is essential for the function of larger macromolecular complexes and the tuning of extracellular matrix biology. Its content and sulfation pattern are critical for the biological interactions and functions of the glycosaminoglycans in which it is found.
Not applicable; iduronic acid is a saccharide residue, not a direct drug target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Iduronic acid (IdoA).